vimarsana.com
Home
Live Updates
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference : comparemela.com
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
- VRDN-001 topline clinical results for THRIVE and THRIVE-2 on track for mid-2024 and year-end 2024 in patients with active and chronic thyroid eye disease , respectively -
- Subcutaneous VRDN-003...
Related Keywords
Massachusetts ,
United States ,
Waltham ,
California ,
San Francisco ,
Clearside Bio ,
Barrett Katz ,
Steve Mahoney ,
Compensation Committee ,
Viridian Therapeutics Inc ,
Key Program Milestones ,
Exchange Commission ,
Nasdaq ,
Viridian Therapeutics ,
Chief Executive Officer ,
Healthcare Conference ,
Investigational New Drug Application ,
Eye Disease Portfolio ,
Fcrn Portfolio ,
Thomas Ciulla ,
Chief Medical Officer ,
Chief Development Officer ,
Inducement Grant ,
Incentive Plan ,
Nasdaq Listing Rule ,
Private Securities Litigation Reform Act ,
Quarterly Report ,
Markets ,
comparemela.com © 2020. All Rights Reserved.